Literature DB >> 26404052

Involvement of AMPK, IKβα-NFκB and eNOS in the sildenafil anti-inflammatory mechanism in a demyelination model.

Ana Karolina Santana Nunes1, Catarina Rapôso2, Sura Wanessa Santos Rocha3, Karla Patrícia de Sousa Barbosa4, Rayana Leal de Almeida Luna4, Maria Alice da Cruz-Höfling5, Christina Alves Peixoto4.   

Abstract

Sildenafil (Viagra®) has recently been found to have a neuroprotective effect, which occurs through the inhibition of inflammation and demyelination in the cerebellum. However, the mechanism of action of sildenafil remains unknown. AMPK, the regulatory protein of the lipid and glucose metabolism, plays a protective role by activating the eNOS enzyme. The production of a nanomolar concentration of NO by eNOS has an anti-inflammatory effect through the cGMP signaling pathway and plays an important role in the regulation of the nuclear transcription factor (NFkB), preventing the expression of inflammatory genes. The present study investigated whether AMPK-eNOS-NO-cGMP-IКβα-NFkB is involved in the mechanism of action of sildenafil in a cuprizone-demyelination model. Neuroinflammation and demyelination induced by cuprizone in rodents have been widely used as a model of MS. In the present study, five male C57BL/6 mice (7-10 weeks old) were used. Over a four week period, the groups received: cuprizone (CPZ) 0.2% mixed in feed; CPZ in the diet, combined with the administration of sildenafil (Viagra®, Pfizer, 25mg/kg) orally in drinking water, starting concurrently (sild-T0) or 15 days (sild-T15) after the start of CPZ. Control animals received pure food and water. The cerebella of the mice were dissected and processed for immunohistochemistry, immunofluorescence (frozen), western blotting and dosage of cytokines (Elisa). CPZ induced an increase in the expression of GFAP, IL-1β TNF-α, total NFkB and inactive AMPK, and prompt microglia activation. CPZ also induced a reduction of IKβα. The administration of sildenafil reduced the expression of the pro-inflammatory cytokines IL-1β and TNF-α and increased the expression of the anti-inflammatory cytokine IL-10. In addition, the administration of sildenafil reduced expression of GFAP, NFkB, inactive AMPK and iNOS, and increased IKβα. Interestingly, sildenafil also reduced levels of NGF. In general, the sild-T0 group was more effective than sild-T15 in improving clinical status and promoting the control of neuroinflammation. The present study offers evidence that sildenafil has anti-inflammatory and neuroprotective effects, which are probably achieved through modulation of AMPK-IKβα-NFκB signaling. In addition, eNOS may play a role in the sildenafil neuroprotective mechanism, contributing to the activation of AMPK. However, other pathways such as MAPK-NFkB and the downstream proteins AMPK (AMPK-SIRT1-NFκB) should also be further investigated. An understanding of these mechanisms of action is critical for the clinical use of sildenafil to control neuroinflammation in neurodegenerative diseases such as MS.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AMPK; Cuprizone; Demyelination; NFkB; Neuroinflammation; Sildenafil

Mesh:

Substances:

Year:  2015        PMID: 26404052     DOI: 10.1016/j.brainres.2015.09.008

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  20 in total

Review 1.  Potential for Ketotherapies as Amyloid-Regulating Treatment in Individuals at Risk for Alzheimer's Disease.

Authors:  Matthew K Taylor; Debra K Sullivan; Jessica E Keller; Jeffrey M Burns; Russell H Swerdlow
Journal:  Front Neurosci       Date:  2022-06-16       Impact factor: 5.152

Review 2.  The Interplay between cGMP and Calcium Signaling in Alzheimer's Disease.

Authors:  Aileen Jehle; Olga Garaschuk
Journal:  Int J Mol Sci       Date:  2022-06-24       Impact factor: 6.208

Review 3.  Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism.

Authors:  Fatima Iqbal; Wendy S Baker; Madiha I Khan; Shwetha Thukuntla; Kevin H McKinney; Nicola Abate; Demidmaa Tuvdendorj
Journal:  Br J Pharmacol       Date:  2017-03-23       Impact factor: 8.739

Review 4.  How do phosphodiesterase-5 inhibitors affect cancer? A focus on glioblastoma multiforme.

Authors:  Mehdi Sanati; Samaneh Aminyavari; Hamid Mollazadeh; Bahram Bibak; Elmira Mohtashami; Amir R Afshari
Journal:  Pharmacol Rep       Date:  2022-01-20       Impact factor: 3.024

5.  Roles of Simvastatin and Sildenafil in Modulation of Cranial Irradiation-Induced Bystander Multiple Organs Injury in Rats.

Authors:  Engy Refaat Rashed; Mohamed Khairy Abdel-Rafei; Noura Magdy Thabet
Journal:  Inflammation       Date:  2021-08-21       Impact factor: 4.092

6.  Chronic inflammation and apoptosis propagate in ischemic cerebellum and heart of non-human primates.

Authors:  Sandra A Acosta; Sherwin Mashkouri; Diana Nwokoye; Jea Y Lee; Cesar V Borlongan
Journal:  Oncotarget       Date:  2017-06-01

7.  Ginkgolide A Ameliorates LPS-Induced Inflammatory Responses In Vitro and In Vivo.

Authors:  Yan Li; Yannan Wu; Xinlei Yao; Fang Hao; Chunlei Yu; Yongli Bao; Yin Wu; Zhenbo Song; Ying Sun; Lihua Zheng; Guannan Wang; Yanxin Huang; Luguo Sun; Yuxin Li
Journal:  Int J Mol Sci       Date:  2017-04-10       Impact factor: 5.923

Review 8.  Sildenafil Can Affect Innate and Adaptive Immune System in Both Experimental Animals and Patients.

Authors:  Monika Kniotek; Agnieszka Boguska
Journal:  J Immunol Res       Date:  2017-02-20       Impact factor: 4.818

9.  Sildenafil ameliorates right ventricular early molecular derangement during left ventricular pressure overload.

Authors:  Yousuke Imai; Taro Kariya; Masaki Iwakiri; Yoshitsugu Yamada; Eiki Takimoto
Journal:  PLoS One       Date:  2018-04-05       Impact factor: 3.240

10.  Roscovitine protects murine Leydig cells from lipopolysaccharide-induced inflammation.

Authors:  Tiancheng Xie; Guanghui Hu; Binbin Dong; Yangye Yan; Min Liu; Xudong Yao; Junhua Zheng; Yunfei Xu
Journal:  Exp Ther Med       Date:  2017-03-20       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.